French ophthalmologist, Henri Parinaud, first described Parinaud syndrome in the late 1800s. Parinaud described it in a series of case reviews of patients with disturbances of associated eye movements and gaze paralysis. He attributed the cause of this condition to a lesion of the quadrigeminal area. This condition is variously known as the Sylvian aqueduct syndrome, dorsal midbrain syndrome, Pretectal syndrome, and Koerber-Salus-Elschnig syndrome. The original description by Henri Parinaud included upgaze palsy and convergence paralysis. However, the definition of Parinaud syndrome has now been widened to include the triad of upgaze paralysis, convergence retraction nystagmus, and pupillary light-near dissociation. Also, it may sometimes include conjugate downgaze in primary position and rarely downgaze palsy.
The causes of Parinaud syndrome include pineal gland tumors, midbrain infarctions, multiple sclerosis, midbrain hemorrhage, encephalitis, arteriovenous malformations, infections (toxoplasmosis), trauma, obstructive hydrocephalus, and sometimes, tonic-clonic seizures. There have been reports of this condition following brachytherapy instillation. However, the most common causes are a pineal gland tumor and other midbrain pathologies like hemorrhage and infarction. The underlying cause of Parinaud syndrome is also found to vary with age. Neoplastic causes are more common in children and young adults, and vascular causes are more common in the middle-aged and older populations.
Parinaud's syndrome usually presents as a sporadic condition. The most common causes are pineal gland tumors and midbrain infarction. Some studies have described that up to 65% of cases are due to primary midbrain lesions like strokes, hemorrhages, and neoplasms and up to 30% of cases were due to Pineal gland tumors causing pressure on the reflex centers in the Quadrigemina(dorsal midbrain).
The classic triad of upgaze paly, convergence retraction nystagmus and pupillary light-near dissociation was seen in about 65% of patients with Parinaud's syndrome.
The constellation of signs and symptoms of Parinaud syndrome are caused by compression of the rostral midbrain and pretectum at the level of the superior colliculus.
The characteristic symptom of Parinaud syndrome is limited conjugate upgaze. It occurs because of the involvement of the vertical gaze centers, which are in proximity to the Superior colliculus, with some of the main nuclei being the interstitial nuclei of Cajal and the rostral interstitial nucleus of the Medial Longitudinal Fasciculus (riMLF). Downgaze is classically preserved, but the reason for this is not entirely explained. It has been suggested that the pathways for downward gaze are directed medially from the rostral interstitial nucleus of the Medial Longitudinal Fasciculus (MLF); whereas, the fibers for upward gaze are directed laterally from the Medial Longitudinal Fasciculus and decussate in the posterior commissure. This makes them more susceptible to the pressure effect of space occupying lesions. However, a condition called Reverse Parinaud syndrome has also been described. In this condition, there is downgaze palsy instead of upgaze palsy, and the patient presents with the combination of downgaze palsy with convergence weakness and pupillary light-near dissociation. This is an extremely rare condition with very few reported cases.
Another component of the triad of Parinaud syndrome is convergence- retraction nystagmus which is characterized by an irregular, jerky nystagmus, associated with convergence and retraction of both eyes, especially on attempted upgaze. It has been postulated that convergence retraction nystagmus is caused by damage to the supranuclear fibers, which have an inhibitory effect on the midbrain convergence or divergence neurons. This results in sustained discharge from the medial rectus and other extraocular muscles. Convergence retraction nystagmus is considered a highly localizing sign, pointing to a lesion of the dorsal midbrain.
The third component of the Parinaud syndrome triad is pupillary involvement. There is poor pupillary constriction to light but preserved constriction with convergence. The pupillary light reflex fibers synapse at the pretectal nucleus and the pass to the Edinger-Westphal nucleus of the same side and the contralateral side through the posterior commissure, making them susceptible to external compressive effects of mass lesions. It is thought that the fibers for the near reflex are located more ventrally. Thus they are spared in Parinaud syndrome, which is a dorsal midbrain syndrome.
Patients may also present with lid retraction in the primary position, which is called the Collier sign. The cause is thought to be due to damage to the levator inhibitory fibers at the posterior commissure.
Parinaud syndrome is classically described by the triad of upgaze palsy, convergence retraction nystagmus, and pupillary hyporeflexia. Patients may complain of difficulty looking up, blurred near vision, diplopia, oscillopsia, and there may be associated neurological symptoms. Many studies have described diplopia as the most common symptom. It is seen in 65% of patients. Diplopia may be caused either by skew deviation or associated fourth nerve palsy. Vertical diplopia is classically seen and can be very disabling to the patient. Some patients may also a complaint of blurred vision, and it could be due to accommodation spasm. For many, the most incapacitating symptom is the inability to elevate the eyes, often causing a compensatory chin up position.
The signs of Parinaud syndrome include:
A thorough neurological examination is indicated in all patients. Visual acuity examination, visual fields, color vision, pupillary examination, and fundoscopy are indicated. Because of the wide variety of causes of this condition, a thorough workup including neuroimaging is mandatory to discover the underlying cause. Infection screening, serum protein electrophoresis, and thyroid function tests may also be done. Other investigations which may be done include cerebrospinal fluid studies, serum acetylcholine receptor antibodies, and nerve conduction studies.
Treatment is primarily directed toward the underlying cause. Symptoms may be completely reversed in patients with early hydrocephalus. The aim of treatment is, therefore, to treat the underlying condition urgently before permanent damage occurs. Persistent upgaze palsies may be corrected surgically. The surgical options include inferior rectus recession, superior rectus resection, and superior transposition of medial and lateral rectus muscles. All these procedures improve upgaze position and abnormal head position and ultimately improve the severity of retraction nystagmus. Visual training and tracking exercises are another options, which can also be used in patients with persistent gaze palsies.
Parinaud syndrome is best managed by a multidisciplinary team including neurology and ophthalmology nurses. The key is to make the diagnosis of the primary disorder and manage it. However, some patients with chronic symptoms may need eyelid surgery.
The outcomes for patients with parinaud syndrome depend on the cause.
|||The pretectal syndrome: 206 patients., Keane JR,, Neurology, 1990 Apr [PubMed PMID: 2320246]|
|||Parinaud «plus» syndrome in a patient with dysgerminoma., Burgueño-Montañés C,Santalla-Castro C,Peña-Suárez J,, Archivos de la Sociedad Espanola de Oftalmologia, 2016 Feb 18 [PubMed PMID: 26900044]|
|||Primary central nervous system lymphoma presenting as Parinaud syndrome., Cheung T,Proulx A,Fraser JA,, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2011 Oct [PubMed PMID: 21995994]|
|||Parinaud syndrome: a 25-year (1991-2016) review of 40 consecutive adult cases., Shields M,Sinkar S,Chan W,Crompton J,, Acta ophthalmologica, 2016 Oct 24 [PubMed PMID: 27778456]|
|||Convergence-Retraction Nystagmus Associated with Dorsal Midbrain Lesions in Three Dogs., Crawford AH,Beltran E,Lam R,Kenny PJ,, Journal of veterinary internal medicine, 2016 Jul [PubMed PMID: 27169871]|
|||Teaching Neuro<i>Images</i>: Acute Parinaud syndrome., Swinkin E,Bui E,, Neurology, 2017 Apr 18 [PubMed PMID: 28416623]|
|||Ophthalmological outcomes of patients treated for pineal region tumors., Hankinson EV,Lyons CJ,Hukin J,Cochrane DD,, Journal of neurosurgery. Pediatrics, 2016 Jan 22 [PubMed PMID: 26799411]|